Actively Recruiting
Phase I Study of Personalized KSX01-TCRT Cell Therapy for Adults With Advanced Solid Tumors Evaluating Safety and Effectiveness in Patients Aged 18 to 70
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-03-26
12
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating personalized KSX01-TCRT cell therapy in patients with advanced solid tumors that are incurable or metastatic and have failed standard treatments. This early phase I clinical trial aims to investigate the safety and effectiveness of this therapy in a single-arm, open-label setting. The study is divided into two parts a dose escalation phase and a dose expansion phase, where the dose used must have passed safety assessments during escalation. Participants receive personalized KSX01-TCRT, a biological therapy using their own T cells modified to target tumors. The trial begins with screening and tissue collection to identify suitable TCR sequences for therapy. After confirming safety in the dose escalation stage Part A, selected patients enter the dose expansion stage Part B for further treatment with the established dose. Throughout the study, participants undergo various assessments including tumor tissue collection, blood tests, organ function evaluations, and performance status checks. Safety and tumor response are monitored for about two years. Additional evaluations include HLA typing, TCR sequencing, and regular follow-ups, with careful monitoring of organ functions and adverse events. The trial duration depends on individual patient response and treatment course.
CONDITIONS
Brief Title
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
Research Team
C
clinical trials ksh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here